McKesson Reaches New 52-Week High (MCK)

NEW YORK ( TheStreet) -- McKesson (NYSE: MCK) hit a new 52-week high Monday as it is currently trading at $119.36, above its previous 52-week high of $119.32 with 402,132 shares traded as of 3:30 p.m. ET. Average volume has been 1.2 million shares over the past 30 days.

McKesson has a market cap of $27.01 billion and is part of the services sector and wholesale industry. Shares are up 21.9% year to date as of the close of trading on Friday.

McKesson Corporation, together with its subsidiaries, delivers pharmaceuticals, medical supplies, and health care information technologies to the healthcare industry primarily in the United States. It operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates McKesson as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full McKesson Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

House Committee: 2 Pharmacy Managers Sent 12.3 Million Opioid Doses to 1 Store

House Committee: 2 Pharmacy Managers Sent 12.3 Million Opioid Doses to 1 Store

Who Says There Are No Second Chances?

Who Says There Are No Second Chances?

Medical Supply Stocks Get Hit in Latest Example of the 'Amazon Effect'

Medical Supply Stocks Get Hit in Latest Example of the 'Amazon Effect'

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Drug Supply Chain Stocks Dip After White House Recommendations on Drug Pricing

Drug Supply Chain Stocks Dip After White House Recommendations on Drug Pricing